|
US2015183846A1
|
|
Human fusion proteins comprising single chain tnfalpha and targeting domains
|
|
WO2014094799A1
|
|
Ubiquitin moieties as a means for prolonging serum half-life
|
|
US2013183265A1
|
|
Mia-2 protein
|
|
EP2721056A1
|
|
Human fusion proteins comprising interferons and targeted modified ubiquitin proteins
|
|
WO2012172054A1
|
|
Modified multimeric ubiquitin proteins binding vegf-a
|
|
WO2012171541A1
|
|
Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
|
|
WO2011131491A1
|
|
Method of producing soluble recombinant protein
|
|
CA2782093A1
|
|
Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin
|
|
EP2380975A1
|
|
Method for producing recombinant thrombin
|
|
EP1955712A1
|
|
Multimeric conjugate
|
|
EP1925664A1
|
|
Artificial binding proteins based on a modified alpha helical region of ubiquitin
|
|
DE102004049479A1
|
|
Protein conjugates for use in therapy, diagnosis and chromatography
|
|
DE10360483A1
|
|
Expression vector and its use
|
|
DE10324447A1
|
|
Generation of artificial binding proteins based on ubiquitin
|
|
DE10317369A1
|
|
proNGF as a pharmaceutically effective agent for the treatment of demyelinating diseases
|
|
DE10313341A1
|
|
Use of proNGF, especially for wound healing of the cornea and skin
|
|
DE10305082A1
|
|
MIA-2 protein
|
|
DE10161577A1
|
|
Process for the renaturation of proteins
|
|
DE10059336A1
|
|
Production of recombinant BMP-2
|
|
DE19932688A1
|
|
Design of beta-sheet proteins of gamma-II-crystalline antibody-like
|
